Search

Author/Creator Balas, Bogdana

1. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Issue 2 (February 2016)

Authors:
Shaw, Alice T; Gandhi, Leena; Gadgeel, Shirish; Riely, Gregory J; Cetnar, Jeremy; West, Howard; Camidge, D Ross; Socinski, Mark A; Chiappori, Alberto; Mekhail, Tarek; Chao, Bo H; Borghaei, Hossein; Gold, Kathryn A; Zeaiter, Ali; Bordogna, Walter; Balas, Bogdana; Puig, Oscar; Henschel, Volkmar; Ou...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 2(2016:Feb.)
Page Start:
234
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects. Issue 4 (28th September 2016)

Authors:
Morcos, Peter N.; Guerini, Elena; Parrott, Neil; Dall, Georgina; Blotner, Steven; Bogman, Katrijn; Sturm, Carolina; Balas, Bogdana; Martin‐Facklam, Meret; Phipps, Alex
Journal:
Clinical pharmacology in drug development
Issue:
Volume 6:Issue 4(2017)
Page Start:
388
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Optimized Alectinib Dose Regimen for Treatment of Patients With ALK‐Positive Non‐Small Cell Lung Cancer Based on Robust Pharmacometric Analyses and Clinical Evidence. Issue 5 (8th August 2021)

Authors:
Frey, Nicolas; Bordogna, Walter; Balas, Bogdana; Ruf, Thorsten; Archer, Venice; Guerini, Elena
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 110:Issue 5(2021)
Page Start:
1162
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. (December 2019)

Authors:
Pérol, Maurice; Pavlakis, Nick; Levchenko, Evgeny; Platania, Marco; Oliveira, Julio; Novello, Silvia; Chiari, Rita; Moran, Teresa; Mitry, Emmanuel; Nüesch, Eveline; Liu, Ting; Balas, Bogdana; Konopa, Krzysztof; Peters, Solange
Journal:
Lung cancer
Issue:
Volume 138(2019)
Page Start:
79
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer. (21st September 2021)

Authors:
Hsu, Joy C.; Jaminion, Felix; Guerini, Elena; Balas, Bogdana; Bordogna, Walter; Morcos, Peter N.; Frey, Nicolas
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 10:Number 11(2021)
Page Start:
1357
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. (January 2020)

Authors:
Ou, Sai-Hong Ignatius; Gadgeel, Shirish M.; Barlesi, Fabrice; Yang, James Chih-Hsin; De Petris, Luigi; Kim, Dong-Wan; Govindan, Ramaswamy; Dingemans, Anne-Marie; Crino, Lucio; Léna, Hervé; Popat, Sanjay; Ahn, Jin Seok; Dansin, Eric; Mitry, Emmanuel; Müller, Barbara; Bordogna, Walter; Balas, Bogda...
Journal:
Lung cancer
Issue:
Volume 139(2020)
Page Start:
22
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗